title: Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  To assess the effect of ranolazine on systemic vascular function in patients with type II diabetes mellitus (T2DM).
  
  
  METHODS
  We randomized 30 consecutive T2DM patients with no evidence of cardiovascular disease and no insulin therapy to receive one of the following 3 forms of treatment in a blinded fashion: ranolazine, 375 mg bid for 3 weeks (group 1); ranolazine, 375 mg bid for 2 weeks, followed by placebo bid for 1 week (group 2); placebo bid for 3 weeks (group 3). Flow-mediated dilation (FMD) and nitrate-mediated dilation (NMD) of the right brachial artery were assessed at baseline and after 48 h, and 2 and 3 weeks.
  
  
  RESULTS
  FMD and NMD were similar among groups at baseline. Compared to the basal value, FMD significantly improved after 2 weeks in group 1 and in group 2 (p < 0.01 for both), but not in group 3. At 3 weeks, FMD remained improved, compared to baseline, in group 1 (p < 0.05), whereas returned to basal values in group 2 (p = 0.89 vs. baseline). No changes in NMD were observed in any group.
  
  
  CONCLUSIONS
  In this controlled study, ranolazine was able to improve endothelial function in T2DM patients.
authors.affiliation: Institute of Cardiology, Università Cattolica del Sacro Cuore, Rome, Italy.
authors.forename: Priscilla
authors.initials: P
authors.lastname: Lamendola
authors.forename: Roberto
authors.initials: R
authors.lastname: Nerla
authors.forename: Dario
authors.initials: D
authors.lastname: Pitocco
authors.forename: Angelo
authors.initials: A
authors.lastname: Villano
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Scavone
authors.forename: Alessandra
authors.initials: A
authors.lastname: Stazi
authors.forename: Giulio
authors.initials: G
authors.lastname: Russo
authors.forename: Antonino
authors.initials: A
authors.lastname: Di Franco
authors.forename: Alfonso
authors.initials: A
authors.lastname: Sestito
authors.forename: Giovanni
authors.initials: G
authors.lastname: Ghirlanda
authors.forename: Gaetano A
authors.initials: GA
authors.lastname: Lanza
authors.forename: Filippo
authors.initials: F
authors.lastname: Crea
mesh_terms: D000083:Acetanilides / Q000494:pharmacology*; D001158:Arteries / Q000187:drug effects* / Q000503:physiopathology*; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology*; D000069458:Ranolazine; D016037:Single-Blind Method
chemical_list: D000083:Acetanilides; D004791:Enzyme Inhibitors; D010879:Piperazines; D000069458:Ranolazine